Compounded Tirzepatide: The 2026 Complete Guide

2. FDA-approval status: what compounding means legally

FDA approval applies to a specific finished drug product made by a specific manufacturer: its formulation, manufacturing process, labeling, and clinical trial evidence are reviewed and approved as a package. Compounded medications sit in a different legal category. They are prepared by a state-licensed compounding pharmacy for an individual patient under a physician prescription, as permitted by Section 503A of the Federal Food, Drug, and Cosmetic Act, and the finished preparation itself is not reviewed or approved by the FDA.

Three practical consequences follow. First, compounded tirzepatide is not FDA-approved as a final product. Second, it is not a generic: a generic drug goes through its own FDA review demonstrating equivalence to a reference product, and no compounded preparation does that. Third, it is not equivalent to or interchangeable with any FDA-approved medication, and clinical trial results generated by FDA-approved products do not describe compounded preparations.

Oversight of compounding comes from state boards of pharmacy, which license and inspect compounding pharmacies, and from United States Pharmacopeia standards (USP 795 and 797) that govern how preparations are made. For the Section 503A patient-specific model described on this page, a valid prescription from a licensed physician for an identified individual patient is required.

Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication. Compounded GLP-1 medications are prepared by state-licensed compounding pharmacies based on a physician's prescription for an individual patient. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective manufacturers, which are not affiliated with and do not endorse Majesta Health. Those are separate FDA-approved products that we do not sell, and they are named here only to make that distinction clear. Results may vary. Not a substitute for professional medical advice.

At Majesta Health, compounded tirzepatide injection (the Performance plan) is $339 your first month, then $439 a month. One price includes the physician consultation, the medication, and shipping. A $20 medical consultation fee is included in your first month, collected on a pass-through basis to the prescribing provider where applicable. Cancel anytime.

Both plans include physician consultation, compounded medication, discreet shipping, and unlimited messaging with your care team. Cancel anytime.

What is actually in your monthly price?

• Physician evaluation and ongoing care
• Compounded medication from a US-licensed compounding pharmacy
• Discreet, temperature-controlled shipping
• Unlimited messaging with the care team
• A $20 medical consultation fee where applicable, collected on a pass-through basis to the prescribing physician

For a deeper cost breakdown, including hidden fees to watch for at other providers, read our full compounded tirzepatide cost guide.

Yes, when properly prescribed and dispensed under the federal compounding framework. Pharmacy compounding in the United States is governed by:

• Section 503A of the Federal Food, Drug, and Cosmetic Act. Permits compounding by a state-licensed pharmacist for an identified individual patient based on a valid prescription.
• Section 503B of the Federal Food, Drug, and Cosmetic Act. A separate framework for FDA-registered outsourcing facilities, which compound at larger scale and are not required to work from patient-specific prescriptions. It is distinct from the 503A patient-specific model described on this page.
• State Boards of Pharmacy. License and inspect compounding pharmacies operating within each state.
• State medical boards and the Ryan Haight Act. Govern telehealth prescribing, including the requirement that prescribers be licensed in the patient's state.

What is not allowed: copying an FDA-approved drug solely because it is cheaper or more convenient. The FDA has clarified that compounding is appropriate when a clinical need exists for an individual patient that cannot be met by the FDA-approved product, including documented allergies, dosing needs, formulation differences, and documented availability concerns.

Majesta Health works exclusively with US-licensed physicians (through MD Integrations, our telehealth provider group partner) and state-licensed 503A compounding pharmacy partners. The pharmacy that prepares your prescription is named on your prescription label and disclosed before your medication ships.

Semaglutide is a GLP-1 receptor agonist: one pathway. Tirzepatide is a dual GIP and GLP-1 receptor agonist: two pathways. Both slow gastric emptying, reduce appetite, and support post-meal glucose control. The honest framing is that this is a clinical decision, not a ranking: which mechanism fits you depends on your history, your tolerance of side effects, your goals, and cost. Some patients are better served by one, some by the other.

At Majesta Health both are offered as injections: semaglutide as the Essential plan ($179 first month, then $299 a month) and tirzepatide as the Performance plan ($339 first month, then $439 a month). You do not choose alone: the physician who reviews your file recommends the plan that fits your case, and switching later is a clinical conversation, not a penalty.

For the semaglutide side of the choice, read the compounded semaglutide 2026 guide.

The compounded GLP-1 market grew quickly between 2022 and 2025. Most providers are legitimate. Some are not. Walk away from any provider that does one of the following:

• Promises specific pounds lost or specific clothing sizes
• Ships medication without a physician evaluation, or claims no prescription is required
• Markets the medication as FDA-approved, or hides the compounded status
• Does not name its partner compounding pharmacy or refuses to confirm its state licensure
• Uses fake before-and-after photos or testimonials that look stock or copied from other sites
• Prices that are far below the market range without a transparent explanation
• No physical business address, no phone number, and no clear ownership disclosure
• Pressures one-click upsells before a physician has even reviewed your case

The most commonly reported side effects of tirzepatide are gastrointestinal and tend to peak during dose escalation and improve over weeks.

Common (typical of dose increases)

• Nausea (most common)
• Diarrhea or constipation
• Vomiting
• Decreased appetite (intended effect)
• Indigestion or abdominal discomfort
• Mild fatigue
• Injection site reactions

Less common but more serious

• Pancreatitis (severe abdominal pain that radiates to the back)
• Gallbladder disease, including gallstones
• Severe hypoglycemia, especially in patients also taking insulin or sulfonylureas
• Acute kidney injury from dehydration
• Allergic reactions
• Changes in diabetic retinopathy in patients with that condition

Contact your prescribing physician for symptoms that persist beyond expected adjustment windows or that are severe. Seek emergency care for symptoms suggesting pancreatitis, severe allergic reaction, severe dehydration, or severe hypoglycemia. For practical management tips, see our GLP-1 side effects management guide.

• FDA, Compounding and the FDA: Questions and Answers
• FDA, Section 503A of the Federal Food, Drug, and Cosmetic Act
• USP, General Chapters 795, 797, 800 (compounding standards)

This guide reflects publicly available information as of 2026-08-28. It is educational and does not substitute for personalized medical advice. Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any FDA-approved medication. Compounded GLP-1 medications are prepared by state-licensed compounding pharmacies based on a physician's prescription for an individual patient. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective manufacturers, which are not affiliated with and do not endorse Majesta Health. Those are separate FDA-approved products that we do not sell, and they are named here only to make that distinction clear. Results may vary. Not a substitute for professional medical advice.